SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (38)9/25/1996 12:44:00 AM
From: Josh C. Pleasure, M.D.   of 371
 
No, problem. I have found Mr. Herron of IMMU to be very responsive - he always returns calls. I plan to ask some nuc. med people at the local top notch cancer hosp. whether they agree with me that CEA scan has a role in initial work up of colorectal ca patients or just the labeled use - for recurrences. Having seen the data and read the papers (98% ppv for mets when combined with CT, no known HAMA reactions), it would seem to me that I am correct. Of course, the surgeons have to be educated - they understand CT, but Nuc medicine, in the words of Dr. Edmund Kim, is "Unclear medicine."

Of course - as I've stated before, CEA scan is second in importance to the future of IMMU behind LeukoScan - which I don't doubt will be approved. WBC Scans-which Leukoscan will replace-are burdensome to perform - you need to take blood out of patient, label it (or send it somewhere else to be labeled) inject, wait 24 (or 48 or sometimes 72 hours) for results. Leukoscan is a few hours wait, easy to do.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext